Dr. Muhammad Furqan
Claim this profileUniversity of Iowa Healthcare Cancer Services Quad Cities
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
24 reported clinical trials
38 drugs studied
About Muhammad Furqan
Education:
- Obtained MD from the University of Iowa Carver College of Medicine in 2017.
Experience:
- Completed Residency in Radiation Oncology at the University of Iowa Hospitals & Clinics in 2022.
- Finished Fellowship in Stereotactic Body Radiotherapy (SBRT) and Stereotactic Radiosurgery (SRS) at the University of Iowa Hospitals & Clinics in 2023.
- Currently practices as a Radiation Oncologist at University of Iowa Healthcare Cancer Services Quad Cities.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage I
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Muhammad Furqan is currently running
[18F]F-AraG PET Scan Reliability
for Lung Cancer
This pilot study aims to evaluate the test-retest variability of \[18F\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \[18F\]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore these objectives, eligible subjects will undergo two \[18F\]F-AraG PET/CT scans within 7 days of each other prior to receiving treatment. This study is a single-site, open-label, non-randomized, single-arm pilot trial. Patients and care providers will not be blinded to any part of the study.
Recruiting1 award Phase 23 criteria
Temozolomide + Atezolizumab
for Small Cell Lung Cancer
This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving temozolomide and atezolizumab as second or third line treatment may help prolong survival in patients with small cell lung cancer.
Recruiting1 award Phase 215 criteria
More about Muhammad Furqan
Clinical Trial Related1 year of experience running clinical trials · Led 24 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments Muhammad Furqan has experience with
- Pembrolizumab
- Carboplatin
- Durvalumab
- [18F]F-AraG
- Etoposide
- Paclitaxel
Breakdown of trials Muhammad Furqan has run
Lung Cancer
- [18F]F-AraG PET Scan Reliability for Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Ramucirumab + Pembrolizumab for Lung Cancer
Non-Small Cell Lung Cancer
- [18F]F-AraG PET Scan Reliability for Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Ramucirumab + Pembrolizumab for Lung Cancer
Skin Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Muhammad Furqan specialize in?
Muhammad Furqan focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Muhammad Furqan currently recruiting for clinical trials?
Yes, Muhammad Furqan is currently recruiting for 13 clinical trials in Bettendorf Iowa. If you're interested in participating, you should apply.
Are there any treatments that Muhammad Furqan has studied deeply?
Yes, Muhammad Furqan has studied treatments such as Pembrolizumab, Carboplatin, Durvalumab.
What is the best way to schedule an appointment with Muhammad Furqan?
Apply for one of the trials that Muhammad Furqan is conducting.
What is the office address of Muhammad Furqan?
The office of Muhammad Furqan is located at: University of Iowa Healthcare Cancer Services Quad Cities, Bettendorf, Iowa 52722 United States. This is the address for their practice at the University of Iowa Healthcare Cancer Services Quad Cities.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.